Nkarta Inc
NASDAQ:NKTX

Watchlist Manager
Nkarta Inc Logo
Nkarta Inc
NASDAQ:NKTX
Watchlist
Price: 2.42 USD 2.98% Market Closed
Market Cap: 170.8m USD
Have any thoughts about
Nkarta Inc?
Write Note

Nkarta Inc
Investor Relations

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 136 full-time employees. The company went IPO on 2020-07-10. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety and a membrane-bound form of the cytokine IL15 (mbIL-15). The Company’s co-lead product candidates are NKX101 and NKX019. NKX101 is designed to innate NK biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells for understanding NK cell biology.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Paul J. Hastings
CEO & Director
No Bio Available
Ms. Alyssa Levin C.A., CPA
Chief Financial & Business Officer and Principal Accounting Officer
No Bio Available
Dr. David R. Shook M.D.
Chief Medical Officer & Head of Research and Development
No Bio Available
Dr. Nadir Mahmood Ph.D.
President
No Bio Available
Dr. Ralph Brandenberger Ph.D.
Chief Technical Officer
No Bio Available
Mr. Greg Mann
Vice President of Public Affairs and Investor Relations
No Bio Available
Dr. Alicia J. Hager
Chief Legal Officer & Corporate Secretary
No Bio Available

Contacts

Address
CALIFORNIA
South San Francisco
6000 Shoreline Court, Suite 102
Contacts
+14155824923.0
www.nkartatx.com